<DOC>
	<DOCNO>NCT03039673</DOCNO>
	<brief_summary>MIROCALS phase II study ld-IL-2 therapeutic agent ALS . A randomized ( 1:1 ) , placebo-controlled , double-blind , parallel group trial carry assess ld-IL-2 safety clinical efficacy survival functional decline newly diagnose ALS patient treat 18 month . Randomization stratify accord ( ) country ( n = 2 level : UK , France ) ( ii ) site onset ( n= 2 level : bulbar v limb onset ) . The primary objective evaluate clinical efficacy safety experimental drug ( ld IL-2 ) 18 month period order establish proof concept ( PoC ) modify immune response enhancement regulatory T cell modify rate ALS disease progression .</brief_summary>
	<brief_title>MIROCALS : Modifying Immune Response OutComes ALS</brief_title>
	<detailed_description>The secondary objective MIROCALS : To validate new phase-II study design improve efficiency drug development ALS early determination drug response use establish biomarkers ( BMs ) . The aims new trial design : ( ) To shorten future trial duration ALS use early drug respond surrogate marker disease activity ; ( ii ) To establish proof mechanism ( PoM ) test drug ; ( iii ) To identify drug responder status . Additional exploratory objective : ( ) Deep immune &amp; inflammatory phenotyping ( ii ) Brain biomarkers ( iii ) Genomics Transcriptomics</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Main Inclusion criteria Patient 18 year old less 76 year old Possible , Probable , Probable laboratorysupported Definite ALS define El Escorial Revised ALS diagnostic criterion Disease duration &lt; = 24 month Slow Vital capacity &gt; = 70 % normal No prior present riluzole treatment Lumbar puncture accept patient do Main Exclusion criteria Other neurodegenerative disease could explain sign symptom Contra indication lumbar puncture ( history allergy xylocaine , presence contraindicate treatment , coagulation test abnormality , clinically significant coagulopathy thrombocytopenia ) Non authorize treatment Other disease disorder could preclude functional assessment , lifethreatening disorder Any document , active , past present , autoimmune disorder except asymptomatic Hashimoto thyroiditis Using assist ventilation Feeding gastrostomy nasogastric tube Women childbearing potential sexually active man without contraception Pregnant breast feed woman Any clinically significant laboratory abnormality ( except cholesterol , triglyceride , glucose , CK , ferritin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>interleukin-2</keyword>
	<keyword>low-dose interleukin-2</keyword>
</DOC>